• Trial Talks Podcast
  • COVID-19
  • Blog
  • Client Login

Real World Evidence

TargetCancer Foundation Successfully Engages and Empowers Rare Cancer Patients with Medrio

Overview TargetCancer Foundation implemented Medrio’s remote consent function in their TCF-001 TRACK study, which has an objective to determine if rare tumors can benefit from matched molecular therapy. The study is remotely enrolling a total of 400 patients in the United States using electronic informed consent. Medrio’s eClinical solution provides significant benefits to TargetCancer Foundation